Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The safety and efficacy of HBI0101 for the treatment of R/R myeloma

Eyal Lebel • 27 Sep 2023
IMS 2023
Multiple Myeloma Antibodies CAR-T HBI0101 Tocilizumab

In this video, Eyal Lebel, MD, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, discusses results from a study evaluating the safety and efficacy of HBI0101, a novel academic CAR-T, in patients with relapsed/refractory (R/R) multiple myeloma. Dr Lebel summarizes the safety profile of this agent, as well as the response rates, rates of measurable residual disease (MRD) negativity, and progression-free survival (PFS) observed. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eyal Lebel

1:14
The value of enrolling patients with amyloidosis in clinical trials
Eyal Lebel • 27 Sep 2023
2:03
The use of venetoclax in R/R AL amyloidosis
Eyal Lebel • 27 Sep 2023
5:51
Safety of HBI0101 (NXC-201), a novel academic anti-BCMA CAR-T, in R/R AL amyloidosis
Eyal Lebel • 27 Sep 2023

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals